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Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder due
to selective loss of motor neurons (MNs). Mutations in the fused in sarcoma (FUS) gene can
cause both juvenile and late onset ALS. We generated and characterized induced pluripotent
stem cells (iPSCs) from ALS patients with different FUS mutations, as well as from healthy
controls. Patient-derived MNs show typical cytoplasmic FUS pathology, hypoexcitability, as
well as progressive axonal transport defects. Axonal transport defects are rescued by
CRISPR/Cas9-mediated genetic correction of the FUS mutation in patient-derived iPSCs.
Moreover, these defects are reproduced by expressing mutant FUS in human embryonic stem
cells (hESCs), whereas knockdown of endogenous FUS has no effect, conﬁrming that these
pathological changes are mutant FUS dependent. Pharmacological inhibition as well as
genetic silencing of histone deacetylase 6 (HDAC6) increase α-tubulin acetylation, endo-
plasmic reticulum (ER)–mitochondrial overlay, and restore the axonal transport defects in
patient-derived MNs.
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Amyotrophic lateral sclerosis (ALS) is the most commondegenerative disorder of motor neurons (MNs) in adultsand is characterized by the selective death of both upper
and lower MNs. This wasting of MNs leads to progressive
paralysis and death of the patient due to respiratory failure
usually within 2 to 5 years after symptom onset1. In most cases,
ALS is a sporadic disease although ~10% of patients have a clear
family history. Mutations in the superoxide dismutase 1 (SOD1),
the TAR DNA-binding protein (TARDBP), the fused in sarcoma
(FUS), and the chromosome 9 open reading frame 72 (C9orf72)
genes are the most prevalent ones1. No effective treatment is
available for ALS. Riluzole, an FDA-approved drug which has
anti-excitotoxic properties, prolongs life by only a few months2.
Although intensive basic research has been done based on dif-
ferent ALS animal models, none of the discovered strategies has
been successfully translated into a therapy3. As a consequence,
more reliable ALS models are urgently needed. MNs differ-
entiated from patient-derived-induced pluripotent stem cells
(iPSCs) provide a new opportunity to model human disease
starting from patient material and avoiding effects of species
differences and/or overexpression. It can mimic the develop-
mental process in vitro, which could contribute to understand
basic disease mechanisms, especially early pathological changes
that are potentially amenable to drug screening4.
FUS was ﬁrst identiﬁed as an oncogene and was reported as an
ALS-causing gene in 20095–7. It contains a glycine-rich region, an
RNA recognition motif and a nuclear localization signal (NLS).
Many point mutations in FUS have been discovered since then
and a large number of these are situated in the C-terminal NLS
region8. FUS can also cause a rare and very aggressive juvenile
onset ALS5, 9. FUS functions as a DNA/RNA-binding protein and
is involved in multiple aspects of DNA/RNA metabolism8. The
most signiﬁcant pathological change in post mortem tissue is the
cytoplasmic mislocalization of FUS. In iPSC models, cytoplasmic
mislocalization of mutant FUS was reported by three independent
groups in their patient-derived MNs10–12. Cytoplasmic FUS
aggregates were observed by Liu et al.10 for the P525L mutation.
In addition, electrophysiological changes have been frequently
observed in ALS patient-derived MNs11, 13–15. Both hyperexcit-
ability and hypoexcitability have been proposed as pathophysio-
logical defects in these models11, 13–15. A recent study based on
iPSC-derived MNs carrying mutations in C9orf72 or in TARDBP
suggested a switch from hyperexcitability to hypoexcitability,
which could result in MN death12. For FUS, intrinsic membrane
hyperexcitability was presented by Wainger et al.14, whereas
hypoexcitability (characterized by reduced repetitive and spon-
taneous action potentials, lower synaptic activity and lower
intracellular Na+/K+ ratios) was reported by Naujock et al.13
There is no clear explanation why MNs selectively degenerate
in ALS. One hypothesis is based on the observation that MNs
characterized by long axons degenerate ﬁrst and that altered
functions of the most distal sites occurs at initial stages of dis-
ease16. In this dying-back theory, MNs lose their function at the
distal axon and retract back to the MN soma. The longest and
largest axons with the highest metabolic demand seem to be the
most vulnerable ones, which suggest that defects in axonal
transport could be involved in this neurodegenerative process17.
Most of the energy comes from mitochondria transported to the
distal site where they are most needed17. In addition, multiple
cargos such as proteins, mRNAs, lipids, and organelles are mostly
synthesized in the cell body and are transported to the distal part
of the axon to maintain their function18. About 5–20% of the
mitochondria are in very close proximity to the endoplasmic
reticulum (ER), which seems to have an important role in many
neurodegenerative diseases, including ALS19, 20. This region is
called the mitochondria-associated ER membrane (MAM) and is
linked to intracellular trafﬁcking of mitochondria and ER, Ca2+
and phospholipid exchange, energy metabolism, mitochondrial
biogenesis, ER stress responses, and autophagy19, 20. MAMs were
reported to be regulated by TDP-43, which is the protein encoded
by TARDBP and by FUS in transfected cells and in mouse models
through activation of glycogen synthase kinase-3β (GSK-3β)21, 22.
We previously discovered that histone deacetylase 6 (HDAC6)
inhibitors could rescue axonal transport defects in dorsal root
ganglion (DRG) neurons from a transgenic mouse model of the
axonal form of Charcot–Marie–Tooth disease (CMT2)23. In
contrast to the other family members of the HDAC family that
mainly deacetylate histones in the nucleus, HDAC6 is localized in
the cytoplasm and is the major deacetylating enzyme of
α-tubulin24. Acetylation of α-tubulin is important for the binding
of molecular motor proteins to the microtubules25, 26. The
importance of HDAC6 in ALS is illustrated by the fact that
genetic deletion of HDAC6 signiﬁcantly slowed disease progres-
sion and prolonged survival of the mutant SOD1G93A mouse
model27. FUS and TDP-43 have also been reported to regulate
HDAC6 expression28–30. As a consequence, one of our aims was
to investigate the therapeutic potential of HDAC6 inhibition.
To further investigate the pathological mechanism and to
identify potential therapeutic strategies, we generated iPSCs from
ﬁbroblasts of ALS patients carrying different FUS mutations, as
well as from family members without mutations. In addition, we
generated isogenic control lines using the CRISPR-Cas9 tech-
nology and overexpressed wildtype and mutant FUS in human
embryonic stem cells (hESCs). Highly pure MN cultures were
obtained by differentiating these iPSCs or hESCs. The cells
expressing mutant FUS showed cytoplasmic accumulation of
FUS, hypoexcitability, and axonal transport defects. We could
successfully rescue the axonal transport defects by treating the
MNs with HDAC6 inhibitors and by silencing HDAC6 using
antisense oligonucleotides (ASOs). Our results indicate that
axonal transport could have an important role in ALS pathology,
and that HDAC6 inhibition could become a promising ther-
apeutic strategy for FUS-induced ALS.
Results
Generation and characterization of iPSCs and MNs. To
investigate the effect of mutations in FUS on MNs, we generated
iPSCs from ﬁbroblasts of ALS patients with FUS mutations and
controls. Fibroblasts from four different individuals with point
mutations in FUS were used. Three carried a heterozygous R521H
mutation, whereas another one carried a heterozygous P525L
mutation (Supplementary Table 1). For the P525L mutation, we
generated multiple lines to exclude possible heterogeneity
between different iPSC lines of the same patient. Both R521H and
P525L point mutations are localized in the NLS region of the FUS
protein. P525L is an aggressive mutation causing rare early onset
ALS, and also our patient developed the disease at an early age
(Supplementary Table 1)31. In addition, we established two
control iPSC lines (healthy control1 and healthy control2) from
two healthy family members of one of our patients. We also
included another two published healthy controls (healthy con-
trol3 and healthy control4) for patch clamp measurements13.
Reprogramming of ﬁbroblasts was performed using Sendai viral
vectors expressing 4 reprogramming factors (Klf4, Oct3/4, Sox2,
and cMyc). This led to an integration-free conversion of ﬁbro-
blasts into iPSCs. The absence of Sendai virus was conﬁrmed by
qPCR analysis (Supplementary Fig. 1A). The reprogramming
efﬁciency of mutant and control ﬁbroblasts was the same. All
iPSC lines expressed pluripotent stem cell markers as determined
by semi-quantitative PCR for Oct4, Nanog, Sox2, Rex1 (Fig. 1a)
and by immunocytochemical analysis for SSEA4, TRA1-60,
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OCT4, NANOG (Fig. 1b). The pluripotency was also conﬁrmed
by the analysis of in vivo teratoma formation, which contained
the three germ layers (Fig. 1d). All iPSC lines contained the
patient-speciﬁc FUS mutation (Fig. 1c). Furthermore, we estab-
lished one isogenic control line for the 2/2 patient with the
R521H mutation using the CRISPR-Cas9 technology. The
genome-edited iPSC line retained the pluripotency markers
(Supplementary Fig. 2A) and showed markers of the three germ
layers after the embryonic body formation analysis (Supple-
mentary Fig. 2B). The origin of the iPSC lines from the speciﬁc
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ﬁbroblasts was conﬁrmed by the single nucleotide polymorphism
(SNP) analysis (Supplementary Table 2).
To differentiate iPSCs into MNs, we used a slightly modiﬁed
protocol originally described by Maury et al.32 (Fig. 1e). We used
SMAD inhibition and Wnt activation to obtain neuroepithelial
stem cells (NEPs). Subsequently, caudalization was induced by
retinoic acid (RA), followed by induction of ventralization using a
combination of RA, and smoothened agonist (SAG). On day 9,
DAPT, a γ-secretase inhibitor, was added to enhance the
conversion of spinal MN progenitors into post-mitotic spinal
MNs. Immature MNs obtained at day 17 were maintained in
culture with ciliary neurotrophic factor (CNTF) to allow further
maturation. We found no differences in MN differentiation
capability in the different mutant lines, in the isogenic genetically
corrected R521R line, and in the different controls (Fig. 1f;
Supplementary Fig. 2C). A high number of cells stained positive
for the typical markers including HB9, Isl1, ChAT, Synapsin1,
and SMI-32 (Fig. 1f). Quantiﬁcation of Isl1, SMI-32, and ChAT-
positive cells indicated that 70–95% of cells were positive for these
MN markers, without signiﬁcant differences between patients and
controls (Fig. 1g). In addition, the isogenic control line was able
to differentiate into MNs and expressed the MN-speciﬁc markers
at a similar ratio (Supplementary Fig. 2C).
Patient-derived MNs show FUS pathology and hypoexcit-
ability. We used immunostaining to visualize FUS localization in
different cells types. In ﬁbroblasts, nuclear clearance of FUS was
observed in patient lines but not in healthy controls (Fig. 2a). This
phenotype was prominent in ﬁbroblasts carrying the P525L
mutation, whereas it could only be detected in a few cells with the
R521H mutation (Fig. 2a). In undifferentiated iPSCs, both P525L
and R521H showed nuclear clearance of FUS with again a more
pronounced mislocalization of FUS in the P525L mutant line
(Fig. 2a). In mature MNs at day 38 of differentiation, both iPSC-
derived MNs harboring the P525L or the R521H mutation
showed obvious mislocalization of FUS to the neurites, whereas
almost no FUS could be detected in the neurites of healthy
controls (Fig. 2b). Once we corrected the point mutation, the
cytoplasmic FUS localization was fully rescued (Supplementary
Fig. 4A). Consistent with the observation in ﬁbroblasts and in
undifferentiated iPSCs, the P525L mutant lines showed a much
higher amount of FUS mislocalization than the R521H mutant
line. These results conﬁrmed that there is indeed cytoplasmic
mislocalization of the FUS protein in cells derived from FUS-ALS
patients, and that the amount of cytosolic FUS depends on the
nature of the point mutation. In addition, these data demonstrate
that mislocalization of FUS is not MN speciﬁc as it is also
observed in ﬁbroblasts and in undifferentiated iPSCs.
We next performed an electrophysiological evaluation of iPSC-
derived MNs during week 7 after initiation of differentiation.
Both control and mutant MN cultures contained cells ﬁring single
(Supplementary Fig. 3A) or repetitive action potentials
(Supplementary Fig. 3B) during stepwise depolarization in
current clamp mode. This demonstrates that functional MN
maturation from patient and control iPSC lines was not different.
Although the number of electrophysiologically active cells with
spontaneous action potentials revealed no differences between
controls and patient MNs (Fig. 2e), a signiﬁcant decrease in the
frequency of spontaneous action potentials (Fig. 2f), but not in
the amplitude of these spontaneous action potentials (Fig. 2g),
was observed in patient-derived MNs compared with the healthy
controls (Fig. 2c–g). This is in line with the hypoexcitability of
ALS MNs described in previous reports11, 13. To investigate the
Na+ and K+ currents in iPSC-derived MNs, we used whole-cell
voltage clamp mode in a series of depolarizing steps (Supple-
mentary Fig. 3C). After normalization for their membrane surface
(pA/pF), the Na+ peaks were signiﬁcantly lower in patient iPSC-
derived MNs compared with the controls (Supplementary Fig. 3D,
F). As the K+ current peaks were similar (Supplementary Fig. 3E),
this suggests a lower ratio of Na+/K+ channel currents in MNs
derived from mutant FUS iPSCs, which may contribute to the
decreased excitability. In addition, when we recorded sponta-
neous post-synaptic currents in whole-cell voltage clamp mode,
the frequency of synaptic activity was signiﬁcantly decreased in
patient iPSC-derived MNs compared with the healthy controls
(Fig. 2h, j). Similar to what we observed for the spontaneous
action potentials, the proportion of active cells and the
amplitudes did not show any change between patients and
control (Fig. 2i, k). Interestingly, the synaptic input could be
blocked by the application of a glutamatergic AMPA receptor
antagonist, NBQX, and not by a GABA receptor antagonist,
bicuculline (Supplementary Fig. 3G, H).
Progressive axonal transport defects in patient-derived MNs.
Disturbances in axonal transport are considered as an early event
in the pathogenesis of ALS17. Therefore, we measured mito-
chondrial transport in iPSC-derived mature MN cultures in both
patient and control cell lines by using MitoTracker to label
mitochondria in a live cell imaging setup. Kymographs were used
to quantify the total number of moving as well as stationary
mitochondria. In these kymographs, stationary mitochondria are
shown as vertical lines and diagonal lines represent moving ones
(Fig. 3a).
Although the total number of mitochondria was not different
between patient and control MNs at 6 to 7 weeks after initiation
of differentiation (Fig. 3b), patient-derived MNs showed a
signiﬁcant decrease in the number of moving mitochondria
(Fig. 3c). There was no signiﬁcant difference between the different
patient lines. When we measured mitochondrial transport at
different times after plating, a progressive mitochondrial trans-
port defect was observed in patient-derived MNs with a normal
number of moving mitochondria at 2 weeks of differentiation and
a signiﬁcantly reduced number of moving mitochondria starting
from the third week, which became worse over time (Fig. 3e).
Fig. 1 Generation and characterization of iPSCs and MNs from ALS patients and controls. a Semi-quantitative PCR of Oct4, Nanog, Sox2, and Rex1 in
patient iPSCs, control iPSCs, human ESC (ES), and human ﬁbroblasts (HF). b Immunocytochemical characterization of iPSCs for the pluripotency markers
Tra1-60, SSEA4, Oct-4, and Nanog from 2/2, 3/1-2, and 3/2 lines. Scale bar= 50 µm. c Sequencing conﬁrming the heterozygeous R521H and P525L FUS
mutations in patient-derived iPSCs and the absence of FUS mutations in the control iPSC lines. d Hematoxylin–eosin staining identifying three germ layers
in teratomas formed after iPSC injections in immunodeﬁcient mice. Neural-like tissues represent ectoderm, cartilage represents mesoderm, and gut
epithelium represents endoderm. e Schematic protocol of motor neuron differentiation. Y Y-27632, SB SB 431542, LDN LDN-193189, CHIR CHIR99021, RA
retinoic acid, SAG smoothened agonist, DAPT a γ-secretase inhibitor, NEPs neuroepithelial stem cells, MNPs motor neuron progenitors, sMNs spinal
motor neurons, BDNF brain-derived neurotrophic factor, GDNF glial cell line-derived neurotrophic factor, CNTF, ciliary neurotrophic factor. f Staining of
different motor neuron markers (Hb9, Isl1, ChAT, SMI-32, Synapsin1), and DAPI in mutant FUS expressing and control cells at day 38. Scale bar= 50 µm. g
Quantiﬁcation of Isl1-positive (upper panel), ChAT-positive (middle panel), and SMI-32-positive (lower panel) cells expressed relative to the total number
of DAPI-labeled cells. N= 10 images per line. Data are represented as mean± SEM
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Fig. 2 ALS patient-derived MNs exhibit cytoplasmic FUS localization and hypoexcitability. a Immunostaining of FUS in ﬁbroblasts and iPSCs from ALS
patients and healthy controls. Nuclear clearance of FUS was observed in patient ﬁbroblasts. White arrows highlight the nuclear clearance in patient
ﬁbroblasts carrying the R521H or P525L mutation. Scale bar= 70 µm. b Immunostaining of FUS and Tuj1 with DAPI in motor neurons derived from iPSCs of
ALS patients and healthy controls at the fourth week of differentiation. Scale bar= 70 µm. c, d Representative traces of spontaneously occurring action
potentials (APs) in healthy control and FUS iPSC-derived MNs during the seventh week of differentiation. e–g Characterization of MNs differentiated from
iPSCs with spontaneous APs. The relative number of cells (e n= 110 and n= 67 for control and patients, respectively), the frequency of spontaneous APs
(f, n= 48 and n= 34 for control and patients, respectively, Mann–Whitney test, ****P value is 0.0001) and the amplitude (g n= 47 and n= 54 for control
and patients, respectively) were measured. Data values represent mean± SEM. h Representative traces of spontaneous postsynaptic currents (PSCs) in
healthy control and FUS iPSC-derived MNs with typical MN appearance during the seventh week of differentiation. i–k Quantiﬁcation of the relative
number of cells with PSCs (i n= 110 and n= 67 for control and patients, respectively), the PSC frequency (j n= 91 and n= 57 for control and patients,
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derived motor neurons at the fourth week after plating. Images of both soma and neurites are shown. Representative images from three independent
experiments are presented. Scale bar= 100 nm. g Typical kymographs (control 1: 3/2; control 2: 3/3; R521H: 1/2; P525L: 3/1) obtained from motor neurons
loaded with ER Tracker-Red. Scale bar time (vertical): 35 s; scale bar distance (horizontal): 25 μm. h Quantiﬁcation of stationary ER vesicles from MNs
derived from patients with P525L or R521H mutations and control iPSC lines at the fourth week after plating (n= 10, n= 11, n= 12, n= 11 for Ctr1, Ctr2,
R521H, and P525L, respectively). Data values represent mean± SEM. i Quantiﬁcation of moving ER vesicles and ratio of moving to total ER vesicles for
MNs derived from patients with P525L or R521H mutations and control iPSC lines (data are plotted as mean± SEM; one-way ANOVA with post-hoc
Tukey’s test, *, **, ***P values of 0.05, 0.01, and 0.001, respectively). Data values represent mean± SEM
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Although the total number of mitochondria showed a slight
decrease over time (Fig. 3d), the number of moving mitochondria
relative to the total number remained signiﬁcantly lower in MNs
derived from patient iPSCs compared with the controls (Fig. 3e).
As mitochondrial transport defects were previously correlated
with severe mitochondrial damage in a SOD1A4V iPSC model33,
we used electron microscopy (EM) to assess for the integrity of
the mitochondria. However, we could not detect any obvious
morphological changes in the mitochondria in the soma or axons
of patient-derived MNs (Fig. 3f).
We also measured axonal transport of endoplasmic reticulum
(ER) vesicles using ER-tracker (Fig. 3g–i). Patient-derived MNs
also showed a signiﬁcant reduction of moving ER vesicles along
the axons compared with MNs from healthy control iPSC lines
(Fig. 3i). However, the total number of ER vesicles in axons from
MNs of patient iPSC lines was signiﬁcantly reduced compared
with those from controls (Fig. 3h). The fact that the percentage of
moving ER vesicles relative to the total number of ER vesicles was
decreased in patient lines (Fig. 3i) shows that ER vesicle transport
was also decreased, similar to what was observed for mitochon-
drial transport. Altogether, our data indicate that axonal transport
in general is progressively impaired over time in FUS-ALS
patient-derived MNs.
Defects in axonal transport are caused by mutant FUS. To
conﬁrm that the observed phenotypes were due to the mutation
in FUS and to eliminate possible effects of the genetic background
on these phenotypes, we established an isogenic control iPSC line
for one of the patient-derived iPSC lines carrying the R521H
mutation using the CRISPR-Cas9 technology. Sequencing con-
ﬁrmed that the point mutation was corrected (Fig. 4a). As indi-
cated before, differentiation into MNs of this genetically corrected
iPSC line was similar as for the parent line. We performed
mitochondrial transport experiments to assess whether the cor-
rection of the FUS mutation also corrected the defects observed in
MNs derived from the parent iPSC line. We found no reduction
in the total number of mitochondria, nor in the number of
moving mitochondria in MNs from the genetically corrected
R521R iPSC line compared with iPSC-derived MNs from controls
(Fig. 4b). Thus, the axonal transport defect appears to be directly
linked to the mutation in FUS. In addition, a similar rescue also
happened to the cytoplasmic FUS localization (Supplementary
Fig. 4A).
To further conﬁrm the causative relationship between muta-
tions in FUS and the axonal transport deﬁcits, we established
three FUS overexpression H9-hESC lines by inserting a single
copy of the coding region of wildtype FUS, FUS with the R521H
mutation and FUS with the P525L mutation, containing an FRT-
ﬂanked Hyg/TK cassette, into the AAVS1 locus34, 35 via
recombinase-mediated cassette exchange (Fig. 4e). We conﬁrmed
the absence or presence of the different mutations by sequencing
(Fig. 4f). As the construct used contains a Tet-On system, it is
possible to turn on the expression of FUS by adding doxycycline.
In this way, possible effects of (mutant) FUS expression during
the early stages of MN differentiation are circumvented. We
added doxycycline from day 17 of MN differentiation and
assessed FUS pathology and axonal transport on day 38. qRT-
PCR showed an approximately threefold increase in FUS mRNA
levels and this increase was only found after adding doxycycline
(Supplementary Fig. 4B). The induction of FUS
from the transgene inserted into the AAVS1 locus was conﬁrmed
by qRT-PCR using primers in the 3xﬂag region of the FUS
mRNA (Supplementary Fig. 4B). Overexpression of wildtype
FUS and mutant FUS did not change the differentiation capability
from early post mitotic MNs to mature MNs (Supplementary
Fig. 5A, B). However, a signiﬁcant reduction in the number of
moving mitochondria was observed after overexpression of
mutant FUS, whereas wildtype FUS overexpression did
not affect axonal transport (Fig. 4g). A similar situation was also
observed for the cytoplasmic FUS localization (Supplementary
Fig. 4C). Only if we overexpressed mutant FUS, cytoplasmic
FUS was observed and the P525L mutation was always
worse than the R521H mutation (Supplementary Fig. 4C). We
did not observe any defect in axonal transport in control-
derived MNs after knocking down FUS by using ASOs (Fig. 4c,
d). All together, these overexpression and knockdown data
strongly suggest that the axonal transport defects are
due to mutant FUS expression through a gain-of-function
mechanism.
HDAC6 inhibitors rescue axonal transport defects. We next
performed studies to investigate the possible mechanism(s)
responsible for the axonal transport defects in the iPSC-derived
MNs-containing mutant FUS. As indicated before, we ﬁrst assessed
the mitochondrial integrity in mutant FUS and control-derived
MNs by using EM. We could not identify abnormal mitochondrial
morphology in the FUS mutant MNs (Fig. 3g). In addition, we did
not observe any change in neuroﬁlament light chain (NFL)
expression in patient-derived MNs at the fourth week of differ-
entiation (Supplementary Fig. 6). As both mitochondrial and ER
vesicle transport showed defects in mutant FUS MNs, we wondered
whether the mitochondria-associated ER membranes (MAMs)
could be affected19. Therefore, we stained both for mitochondria
and ER, and quantiﬁed the percentage of overlay of both signals. ER
was labeled with protein disulﬁde isomerase (PDI), whereas mito-
chondria were labeled using translocase of the outer mitochondrial
membrane protein-20 (TOM20). Pearson’s correlation coefﬁcient
was used for the analysis. ALS patient-derived MNs all showed a
signiﬁcantly decreased overlap of ER and mitochondrial staining
especially in neurites (Fig. 5a, b). MAMs also inﬂuence phospho-
lipid metabolism. Phosphatidylcholine (PC) is the most common
lipid in the cell and most enriched in the ER19, 36. Cells with
defective MAMs have a lower rate of phosphatidylserine (PS)
conversion to PC than wildtype cells37. Therefore, production of PC
can be used to assess MAM disturbances. We harvested culture
medium at different time points during the in vitro differentiation
process (second, third, and fourth week after plating) and measured
the level of released PC. We observed a reduction of PC in mutant
FUS MNs (Supplementary Fig. 7, Fig. 5c) at the fourth week after
plating. Consistent with the progressive defects found in axonal
transport (Fig. 3e), PC release decreased with prolonged time in
culture (Supplementary Fig. 7).
HDAC6, a class IIb histone deacetylase, is the major enzyme
with α-tubulin deacetylation activity23. In a previous study, we
discovered that HDAC6 inhibitors restore mitochondrial axonal
transport defects in DRG neurons from a CMT disease mouse
model, which correlated with increased α-tubulin acetylation23.
In this study, we assessed the acetylation level of α-tubulin in
MNs differentiated from a mutant FUS line and its isogenic
control. Using western blot analysis, we detected a slight decrease
of acetylated α-tubulin in patient-derived MNs compared with
the isogenic control (Fig. 6d). Moreover, ER-sliding dynamics and
MAM occur on acetylated microtubules38. Therefore, we
investigated the effect of HDAC6 inhibition on MAMs and on
ER vesicle and mitochondrial axonal transport.
First, we used Tubastatin A, which is a highly selective
inhibitor of the deacetylase function of HDAC6, to treat both
patient and healthy control iPSC-derived MNs39. The next day,
cells were ﬁxed for immunostaining or loaded with MitoTracker
and ER-Tracker to measure axonal transport. On the basis of the
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staining results of Tom20 and PDI, the colocalization of ER and
mitochondria was signiﬁcantly increased along axons in patient-
derived MNs after treatment with Tubastatin A (Supplementary
Fig. 9A). This indicates that MAMs were increased. In addition,
the number of moving mitochondria along the axons was
restored in the patient-derived MNs (Supplementary Fig. 9B).
Similarly, both total number and number of moving ER vesicles
were also increased to the same level as in healthy controls
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Fig. 4 Axonal transport defects are caused by mutant FUS. a Genomic DNA sequencing showing the nucleotide change (C to T) in the R521H patient line
(labeled as FUS R521H) and the homozygous nucleotide C in the corrected isogenic control iPSC line (labeled as FUS R521R). b Quantiﬁcations of total
mitochondria, moving mitochondria, and ratio between moving to total mitochondria normalized to a neurite length of 100 µm during 200 s in motor
neurons derived from a control iPSC line, from a patient iPSC line with the R521H mutation and its isogenic control measured at 4 weeks after plating.
(n= 11, n= 14, n= 12, respectively, for wildtype, mutant, and isogenic control, mean± SEM; one-way ANOVA with post-hoc Tukey’s test). c RT-PCR
validation of ASO knockdown of FUS in motor neurons. d Knockdown of FUS did not interfere with total number of mitochondria, moving mitochondria, and
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00911-y
8 NATURE COMMUNICATIONS | 8:  861 |DOI: 10.1038/s41467-017-00911-y |www.nature.com/naturecommunications
(Supplementary Fig. 9C). Tubastatin A had no effect on MNs
derived from healthy controls (Supplementary Fig. 9).
To conﬁrm the Tubastatin A effect, we also tested ACY-738,
which is another newly developed HDAC6 inhibitor with a higher
blood–brain–barrier permeability40. We treated the cells over-
night and a similar rescue was observed in patient-derived MNs
carrying different FUS mutations, whereas there was again no
effect observed in controls (Fig. 5). The overlap between ER and
mitochondrial markers increased 1.5-folds in axons (Fig. 5a, b).
The percentage of moving axonal mitochondria and ER vesicles
in the patient cells also reversed to levels seen in the controls
(Fig. 5d, e). Consistently, a slight increase in the PC level was
observed in medium of patient-derived MNs after treatment with
the HDAC6 inhibitors. These compounds did not change the
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cytoplasmic FUS mislocalization in patient cells (Supplementary
Fig. 8). To conﬁrm the speciﬁcity of these HDAC6 inhibitors, we
used an ASO to knockdown HDAC6 with 50% in our MNs by
treating the MNs for 1 week with the ASO (Fig. 6a, b). Again, an
increase of axonal transport in patient-derived MNs was
observed. Similar as for the HDAC6 inhibitors, no effects were
observed on MNs derived from the isogenic control (Fig. 6c).
Lastly, we investigated the effect of both Tubastatin A and
ACY-738 on the acetylation of α-tubulin using western blot. An
overnight treatment of our iPSC-derived MNs with both drugs
markedly increased the acetylation of tubulin, both in the patient
lines as well as in the isogenic control (Fig. 6d; Supplementary
Fig. 10). In line with what we described before23, there seems to
be a good correlation between the increase in the acetylation level
of α-tubulin and the rescue of axonal transport defects.
Discussion
In this study, we established iPSCs from ﬁbroblasts of four ALS
patients harboring two different point mutations (R521H and
P525L) in the NLS region of FUS, as well as from two healthy
controls. Furthermore, we used CRISPR-Cas9 technology to
correct the point mutation in one of the ALS patient-derived iPSC
lines as an isogenic control line, and we overexpressed wildtype
and mutant FUS in hESCs. In this way, we investigated the
causative relationship between FUS mutations and the observed
defects in MNs derived from these iPSCs/hESCs. In addition, we
developed a highly efﬁcient MN differentiation protocol, which
generated more than 80% of cells with MN morphology,
expressing typical MN markers and exhibiting typical electro-
physiological characteristics. The MNs derived from these iPSCs
of ALS patients exhibited typical FUS mislocalization and
hypoexcitability. In addition, progressive mitochondrial and ER
vesicle transport defects developed in these iPSC-derived MNs.
These axonal transport defects as well as the MAM reduction
could be rescued by HDAC6 inhibition and by genetic knock-
down of HDAC6 using ASOs.
Consistent with previous reports using iPSC models or post-
mortem patient tissue6, 7, 10–12, we observed cytoplasmic FUS
mislocalization in patient cells including ﬁbroblasts, iPSCs, and
MNs. The degree of cytoplasmic mislocalization of FUS was
correlated before with the mutation type and was associated with
the severity of the clinical presentation and the age of disease
onset8. This indicates that cytoplasmic FUS localization is a very
early pathological change, which occurs in different cell types and
of which the severity depends on the type of FUS mutation.
Unlike other studies, we did not observe FUS aggregates in our
mutant lines41. As aggregates were reported to colocalize with
stress-granule markers, we may not have detected FUS aggregates
because we did not apply extra stress to the MNs42. It has been
suggested that the mislocalization of FUS serves as a ﬁrst hit in
the pathophysiological cascade that makes the cell more vulner-
able6. A second hit, such as cellular stress and/or defects in
protein degradation, is proposed to assemble cytoplasmic FUS
into stress granules and could trigger neurodegeneration6.
Several studies demonstrated a number of physiological
changes in different iPSC-derived ALS models. Kiskinis et al.33
reported hyperexcitability in iPSC-derived MNs carrying SOD1,
C9orf72, and FUS mutations based on increased spontaneous
ﬁring and reduced delayed rectiﬁer K+ currents by multielectrode
array recordings. Devlin et al.15 proposed a switch from hyper-
excitation to hypoexcitation of MNs, which was dependent on the
differentiation time of human iPSCs obtained from patients
harboring TARDBP or C9orf72 ALS mutations. Recently, Naujock
et al.13 showed hypoexcitability in MNs derived from mutant
SOD1 and FUS iPSCs differentiated for 7 weeks. Although the
possible change from hyperexcitability to hypoexcitability was
evaluated, only increased synaptic activity but not enhanced AP
ﬁring frequencies was found in cells differentiated in culture for
3–4 weeks. The hypoexcitability was conﬁrmed in our study as
patient-derived MNs presented with a reduced frequency of APs
and postsynaptic currents at week 7 of differentiation. Hypoex-
citation could be a late phenotype, which can eventually cause cell
death. However, we did not observe obvious cell death in the
MNs derived from patient iPSCs. As a consequence, we consider
the hypoexcitability as an early pathological change rather than a
direct cause of cell death.
In addition, we identiﬁed axonal transport defects in MNs
derived of mutant FUS iPSCs. Axonal transport abnormalities
have also been reported in several animal models of ALS, espe-
cially in SOD1 models17, 43, 44. SOD1 mutations can affect neu-
roﬁlaments, mitochondria, and vesicle transport44. Only one
study based on an ALS iPSC-based model has previously iden-
tiﬁed mitochondrial transport defects in MNs derived from ALS
patients carrying an A4V mutation in SOD133. In that study,
mitochondrial damage was observed based on EM and it was
hypothesized to be the cause of the mitochondrial transport
defects33. In the current study, we did not observe obvious
structural changes in the mitochondria of mutant FUS MNs. In
addition, ER vesicle transport along the axons was also decreased
indicating that the disturbance in axonal transport was a more
general problem. These axonal transport defects developed as a
function of time in culture. They were signiﬁcant at the third
week after plating and became progressively worse when cells
were maintained in culture. Defective axonal transport defects
were also observed as a common phenotype in Drosophila models
Fig. 5 Restoration of axonal transport and of ER-mitochondrial overlay by HDAC6 inhibition. a Immunostaining for ER (using mouse PDI antibody) and
mitochondria (using rabbit TOM-20 antibody) of motor neurons derived from iPSC from patients carrying the P525L mutation and healthy controls before
and after an overnight treatment with ACY-738 (1 μM). The separate views show co-localized pixels in the cell body and neurites. Scale bar= 5 µm. b
Quantiﬁcation of the proportion of ER-merged regions and mitochondrial-merged regions relative to the total mitochondrial staining. Data were analyzed
by determining the Pearson’s correlation coefﬁcient using ImageJ (n= 20, mean± SEM, one-way ANOVA with post-hoc Tukey’s test, *, ***P values of 0.05
and 0.001). c Phosphatidylcholine (PC) level in culture media from motor neuron. Media were taken for ELISA after 2 days on the culture at the fourth
week after the start of differentiation. A decrease was observed in patient-derived motor neurons. Representative experiment is shown (mean of technical
duplicates± SD). d Quantiﬁcation of stationary mitochondria, moving mitochondria, and ratio between moving to total mitochondria normalized to a
neurite length of 100 µm in motor neurons derived from patient and healthy control iPSC lines at the fourth week after plating with or without an overnight
treatment with ACY-738 (n= 18, n= 16, n= 15, n= 18, n= 15, n= 13, n= 17, n= 13 for Ctr1 + DMSO, Ctr1 + ACY-738, Ctr2 + DMSO, Ctr2 + ACY-738,
R521H + DMSO, R521H + ACY-738, P525L + DMSO, P525L + ACY-738, respectively, mean± SEM, one-way ANOVA with post-hoc Tukey’s test; *, **P
values of 0.05 and 0.01, respectively). e Quantiﬁcation of stationary ER vesicles, moving ER vesicles, and ratio between moving to total vesicles normalized
to a neurite length of 100 µm in motor neurons derived from patient and healthy control iPSC lines at the fourth week after plating with or without an
overnight treatment with ACY-738 (n= 10, n= 19, n= 11, n= 18, n= 12, n= 12, n= 11, n= 16 for Ctr1 + DMSO, Ctr1 + ACY-738, Ctr2 + DMSO, Ctr2 + ACY-
738, R521H + DMSO, R521H + ACY-738, P525L + DMSO, P525L + ACY-738, respectively, mean± SEM, one-way ANOVA with post-hoc Tukey’s test;
*, **, ***P values of 0.05, 0.01, and 0.001, respectively)
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of TARDBP, FUS, and C9orf7217. These axonal transport deﬁcits
are considered as an early pathological change during the
development of ALS, which might cause dysfunction of the
neuromuscular junctions, which highly rely on energy supplied
by mitochondria and on efﬁcient synaptic cargo delivery to
control proper muscle contraction45. If axonal transport is
hampered in MNs, this leads to the loss of neuromuscular
junctions, axon degeneration, and ﬁnally death of the soma. This
sequence of events has led to the concept of a dying back
mechanism in ALS16. As axonal transport defects were rescued in
the isogenic genetically corrected R521R iPSC-derived MNs, the
mutation itself is sufﬁcient to induce this phenotype. Moreover,
the same mitochondrial transport defects were detected in MNs
generated from hESC in which two different mutant FUS genes
were inducibly overexpressed from within the AAVS1 locus,
whereas wildtype FUS overexpression had no effect. This is
comparable to a previous study detecting axonal branching and
growth defects in primary neuronal cultures of mice over-
expressing mutant FUS (P525L and R521H), whereas no defects
were observed after overexpression of wildtype FUS46. Over-
expression of caz, the Drosophila orthologue of human FUS in
ﬂies, did also not induce axonal transport defects, whereas caz
variants mimicking mutant FUS also induced mitochondrial
transport defects17. Both gain-of-function and loss-of-function
mechanisms have been proposed as the basic mechanism
underlying the pathogenic effect of mutations in FUS. Our data
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Fig. 6 Effect of genetic HDAC6 knockdown and increased acetylation levels of α-tubulin by HDAC6 inhibition. a RT-PCR validation of knockdown by an
antisense oligonucleotide (ASO) against HDAC6 in MNs. b Quantiﬁcation of the RT-PCR results of the gel shown in a illustrating the HDAC6 knockdown
by the ASO. c Knockdown of HDAC6 using an ASO in patient-derived MNs increased axonal transport based on tracking mitochondrial movement (total
number, moving number, and ratio between total and moving mitochondria). Scrambled ASO was used as a negative control (NTC ASO). n= 20,
n= 19, n= 18, n= 10, n= 11, n= 10 for R521R, R521R + NTC ASO, R521R + HDAC6 ASO, R521H, R521H + NTC ASO, R521H + HDAC6 ASO, respectively;
ANOVA with post-hoc Tukey’s test, *P value of 0.05. d Western blot from MNs (R521H mutant line 2/2 and isogenic control R521R), with and without
treatment with ACY-738 or Tubastatin A at day 31 of differentiation. The blot was probed with antibodies directed to acetylated α-tubulin, and GAPDH. e
Schematic representation of our results indicating that HDAC6 inhibition rescues axonal transport defects in FUS-iPSC-derived motor neurons through
increasing acetylation levels of α-tubulin
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strongly suggest that at least the defects in axonal transport are
due to a gain of function of mutant FUS-related toxicity, which is
also consistent with recent studies in a mouse model47. In a recent
study, inhibition of the mitochondrial localization of TDP-43 can
prevent mitochondrial dysfunction and neuronal loss in a TDP-
43M337V mouse model. This indicates that there is a link between
TDP-43 localization and mitochondrial movement, which may
also be true for FUS48.
To gain insights into the mechanism(s) underlying the axonal
transport defects in mutant FUS MNs, we ﬁrst assessed cytoske-
letal changes. Although a previous study demonstrated that NFL
was decreased in mutant SOD1 iPSC MNs49, we did not observe
any signiﬁcant changes in the staining for NFL in both patient and
control cells. Next, we investigated whether MAMs were affected
by FUS mutations. MAMs have multiple functions including lipid
synthesis, mitochondrial dynamics, Ca2+ homeostasis, ER stress,
intracellular trafﬁcking, and autophagy19. Overexpression of TDP-
43 was reported to cause MAM disruption in vivo and in vitro21.
In a recent report, FUS was suggested to activate GSK-3β, which
disrupts MAMs through a VAPB–PTPIP51 interaction22. By
staining for both mitochondria and ER, we found that overlap of
ER and mitochondrial markers was signiﬁcantly lower in FUS
compared with the control MNs. A limitation of our study is that
we could only estimate the MAM reduction using stainings. As
MAMs represent a very small region where the distance between
mitochondria and ER is limited to 10–30 nm, and where only
5–20% of the mitochondrial surface is closely connected to the ER
membranes19, it is difﬁcult to accurately quantify the percentage
of MAMs. As another readout for MAM integrity, phospholipid
release by FUS-mutant MNs was assessed. This demonstrated
signiﬁcantly decreased PC release by FUS-mutant MNs, which
was reversed following genetic correction.
FUS can bind and regulate mRNAs of several motor proteins
including KIF5C, KIF1B, and KIF3A50. All these motor proteins
are involved in axonal transport of mitochondria and vesicles.
KIF5C belong to the Kinesin1 family, which drives anterograde
(=synapse directed) transport of mitochondria along axons51. An
outer mitochondrial protein, Miro1, connects mitochondria with
Kinesin151. Miro1 preferentially localizes in MAM sites and part
of the ER will be transported together with mitochondria based
on this association51. It could be that if MAMs decrease, axonal
transports will decrease because of this reduced Miro1 linkage.
We could rescue both mitochondrial and ER vesicle transport
defects by using two different HDAC6 inhibitors. HDAC6 inhibi-
tion also increased the total number of ER vesicles. These com-
pounds had no effect on healthy control-derived MNs indicating
that axonal transport is already maximal and cannot be increased
by inhibiting deacetylation in these cells. Knockdown of HDAC6
using ASOs also resulted in the same rescue effects on the axonal
transport. This did not only conﬁrm that HDAC6 has an important
role in this rescue effect, it also conﬁrms the speciﬁcity of the
pharmacological HDAC6 inhibitors, used in our study. It was
reported before that the mRNA expression of HDAC6 was regu-
lated by a TDP-43 and FUS complex28. However, we did not
observe any downregulation of HDAC6 expression in MNs derived
of mutant FUS iPSCs. In line with the rescue of axonal transport
deﬁcits in DRG neurons from a mouse model of CMT2 and in a
Drosophila model of Parkinson disease23, 52, we believe that the
therapeutic effect of HDAC6 inhibitors could be related to a more
general effect due to the increase of the acetylation level of α-tubulin
in the microtubules, rather than a (mutant) FUS-speciﬁc effect. This
is also in line with the observation that genetic deletion of HDAC6
in an ALS mouse model with mutant SOD1G93A extended the
lifespan of these mice by maintaining the integrity of the motor
axon, whereas there was no effect on the disease onset27. Our
hypothesis illustrated in Fig. 6d is that an increased acetylation of
α-tubulin increases the proportion of motor proteins binding to the
microtubules, which results in more axonal transport of mito-
chondria and ER vesicles along the axons. This increased binding
overcomes the axonal transport defects induced by different stres-
sors, including mutations in FUS.
Both Tubastatin A and ACY-738 are considered as being
speciﬁc HDAC6 inhibitors. Although Tubastatin A has a higher
selectivity, the advantage of ACY-738 is that it has a better cap-
ability to cross the blood–brain–barrier and that a related com-
pound (ACY-1215, also called ricolinostat) is in clinical trials
without reported side effects until now53. As a consequence,
pharmacological HDAC6 inhibition seems to be an interesting
strategy to counteract general axonal transport defects, which
correlates with an increased acetylation of α-tubulin.
In conclusion, our study showed that point mutations in FUS
result in clear defects in MNs derived from FUS-ALS patients,
which is conﬁrmed by gene editing and overexpression approaches.
Furthermore, we can rescue the defects pharmacologically by
HDAC6 inhibition and by genetic silencing of HDAC6, which
suggests that this could become a new therapeutic strategy for ALS.
Methods
Generation of iPSCs from ﬁbroblasts. Primary human ﬁbroblasts were obtained
from skin biopsies of ALS patients and controls with the approval of the ethical
committee of the University Hospitals Leuven (S50354). The 1/1 and 2/2 samples
were obtained from a 33–year-old and a 71-year-old female patient, respectively.
Both of these patients carry a R521H mutation in FUS. The 3/1 sample is from a
17-year-old male patient carrying a de novo P525L FUS mutation. The 3/2 and
3/3 samples are from the unaffected parents of patient 3/1. The 2/1 sample is from
a presymptomatic patient carrying a R521H mutation. Human iPSC lines were
generated by using the CytoTune®-iPS 2.0 Sendai Reprogramming Kit (Invitro-
gen). Reprogramming factors (Kif4, Oct3/4, Sox2, and cMyc) were transfected by
using non-integrating Sendai virus vectors from the kit. The clearance of these
Sendai-virus vectors was conﬁrmed by using TaqMan® iPSC Sendai Detection Kit
(Invitrogen). Control BJ1 iPSC were generated from BJ ﬁbroblasts (ATCC® CRL-
2522™). The 4/1 and 4/2 are published healthy control iPSCs13.
Gene correction of iPSCs. Creation of isogenic controls of iPSC carrying the
R521H mutation in FUS was performed by CellSystems (Troisdorf, Germany).
iPSCs were transfected with gRNA vector, Cas9 vector, and donor DNA. Trans-
fected cells were selected with puromycin for 2 days. Single clones were genotyped
with genomic DNA PCR and subsequently sequenced. The absence of the FUS
mutation was conﬁrmed by this sequencing.
Recombinase-mediated cassette exchange in hESCs. The FRT-containing hESC
line H9 (WA09) was purchased from WiCell Research Institute (Madison, USA)
and used for recombinase-mediated cassette exchange to establish the FUS hESC-
overexpressing FUS. Wildtype FUS cDNA sequences were purchased from Ori-
Gene Technologies (Rockville, USA). Point mutations were introduced by PCR and
the cDNA was inserted into the AgeI and MluI sites of the pZ:F3‐P–Tet-On-3f-tdT-
F plasmid (constructed by the lab34, 35) to replace the tdT cassette to allow
inducible FUS expression. The RMCE protocol used was described before34, 35.
Puromycin (100–200 ng/ml) and 0.5 μM 1‐(2‐deoxy‐2‐ﬂuoro‐beta‐D‐arabinofur-
anosyl)‐5‐iodouracil (FIAU) were used for colony selection. All PCR primers are
listed in Supplementay Table 2.
Cell cultures. hESCs and human iPSCs were maintained on GeltrexR LDEV-Free
hESC-Qualiﬁed Reduced Growth Factor Basement Membrane Matrix (A1413302,
GibcoTM) in EssentialTM 8 medium (A1517001, GibcoTM) with 1000 U/ml
penicillin–streptomycin. Colonies were routinely passaged with 0.5 mM EDTA
(15575-020, Invitrogen) in Dulbecco’s phosphate-buffered saline (DPBS). Cultures
were routinely analyzed by PCR for mycoplasma contamination.
Teratoma formation and analysis. iPSCs were collected through enzymatic dis-
sociation, 5–10 × 106 cells were resuspended in 100 μl phosphate-buffered saline
(PBS) and injected with 100 μl matrigel (Becton Dickinson) subcutaneously in the
back of immunodeﬁcient RAG2−/− γc−/− mice. Tumors generally developed within
4–8 weeks. Animals were killed for dissection. Teratomas were ﬁxed overnight in
4% paraformaldehyde, washed in 70% ethanol and subsequently embedded in
parafﬁn. After sectioning, the presence of cells from the three germ layers was
assessed following hematoxylin and eosin staining. Hematoxylin–eosin staining was
performed by incubating sections for 2.5 min in Harris’ hematoxylin, washing with
water for 10min, and incubation for 10 s in 0.01 g/ml eosin. These experiments
were approved by the Ethical Committee for animal experiments of the KU Leuven.
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Differentiation of MNs from iPSCs or hESC. Motor neuron differentiation was
performed as described before, with some modiﬁcations32. iPSC clones were
treated with collagenase type IV to form small clusters and resuspended in
EssentialTM 8 medium. During the ﬁrst 2 days, medium was changed every day
with Neuronal basic medium (DMEM/F12 plus Neurobasal medium with N2 and
B27 supplement without vitamin A) supplemented with 40 μM SB431542 (Tocris
Bioscience), 0.2 μM LDN-193189 (Stemgent), 3 µM CHIR99021 (Tocris
Bioscience), and 5 µM Y-27632 (Merck Millipore). From day 3 on, 0.1 µM retinoic
acid (Sigma) and 500 nM SAG (Merck Millipore) was added. From day 8 on,
BDNF (10 ng/ml, Peprotech) and GDNF (10 ng/ml, Peprotech) were added. DAPT
(20 µM, Tocris Bioscience) was added on day 9. Floating clusters were dissociated
into single cells for plating on day 11 by using 0.05% trypsin (GibcoTM).
Motor neuron progenitors were subsequently plated on laminin (20 μg/ml)-coated
12-well plates at 0.5–2 × 105 cells per well. From day 17 on, the cells were switched
to motor neuron maturation medium supplemented with BDNF, GDNF, and
CNTF (each 10 ng/ml, Peprotech) to keep long term cultures. Media were changed
every other day by replacing half of the medium. For rescue experiments, motor
neurons were treated overnight with either 1 µM Tubastatin A (Sigma), 1 µM ACY-
738 (Acetylon Pharmaceuticals Inc., Boston, USA) or an equivalent amount of
DMSO.
Unassisted delivery of ASOs. Locked Nucleic Acid (LNA™) oligonucleotides for
FUS and HDAC6 were purchased from Exiqon (Vedbaek, Denmark), Motor
neuron progenitors were seeded at low plating density of 0.5 × 105 cells per well (12
well plate) at day 10 of motor neuron differentiation. At day 25, oligonucleotides
dissolved in sterilized water were added and mixed. The LNA oligonucleotides were
used at a ﬁnal concentration of 50 nM. The total incubation time before cell lysis or
axonal transport analysis was 1 week.
Patch-clamp experiments. Patch-clamp recordings of iPSC-derived MNs were
performed at room temperature with an inverted microscope (Zeiss) and an EPC-
10 ampliﬁer (HEKA)13. Whole-cell recordings were low-pass ﬁltered and digitized
at 2.9 and 10 kHz, respectively. Patch Master software (HEKA) was used for
recording and for the ﬁnal evaluation of the data. Borosilicate glass pipettes (Sci-
ence Products) were pulled and polished to yield a resistance of 3–4MOhm when
ﬁlled with the internal solution (153 mM KCl, 1 mM MgCl2, 10 mM HEPES, 5 mM
EGTA, and 2 mM Mg-ATP, calibrated to pH 7.3 with KOH; 305 mOsm). Phar-
macological compounds were applied to the external bath solution (142 mM NaCl,
8 mM KCl, 1 mM CaCl2, 6 mM MgCl2, 10 mM glucose, and 10 mM HEPES,
calibrated to pH 7.4 with NaOH; 325 mOsm). NBQX (10 µM, Sigma) or bicuculline
(10 µM, Sigma) were applied via gravity through the modiﬁed SF-77B perfusion
fast-step system (Warner Instruments).
Real-time PCR and sequence analysis. RNA was isolated using an RNeasy kit
(Qiagen) and reverse transcription was performed using SuperScript® III
First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen). Quantitative RT-PCR
was performed using SYBR® Green PCR Master Mix (Applied Biosystems™) on the
7500 Step OnePlus™ Real-Time PCR System (Applied BiosystemsTM). All
samples were run in triplicate and relative quantiﬁcation was done using the ΔΔCt
method with normalization to GAPDH. A list of primers can be found in
Supplementary Table 2. Genomic DNA was isolated using a DNeasy kit (Qiagen)
and sequencing was performed by LGC Genomics (Teddington, UK). The
TaqMan® hPSC Scorecard™ Panel (Life Technologies—A15870—HPSC scorecard
panel 384) kit was used to determine the expression of markers from the three
germ layers.
Western blotting and ELISA. Cells were manually collected on ice and fresh-
frozen cell samples were maintained at −80 °C until further processing. Samples
were hydrolyzed in RIPA buffer (containing 50 mM Tris, 150 mM NaCl, 1% (vol/
vol) NP40, 0.5% sodium deoxycholate (wt/vol), 0.1% SDS (wt/vol) complemented
with protease inhibitors (Complete, Roche Diagnostics, pH 7.6). Protein con-
centrations were determined using the microBCA kit (Thermo Fisher Scientiﬁc
Inc.) according to the manufacturer’s instructions. Western blotting was performed
as described before23. Optical densities were determined using the integrated
density measurement tool of ImageJ (NIH).
For ELISA, the Phosphatidylcholine Colorimetric/Fluorometric Assay Kit
(BioVision) was used to detect phosphatidylcholine level in motor neuron
culture medium according to the manufacturer’s instructions. The medium was
collected after 2 days incubation with cells. No dilution was needed for the
measurements. Absorbance was measured at 540 nm. Because of the large
variation in absolute values between different batches, representative experiments
are shown.
Immunocytochemistry. Cells plated on coverslips were ﬁxed in 4% paraf-
ormaldehyde for 20 min at room temperature and were washed with PBS. Per-
meabilization and blocking was done for 30 min using PBS containing 0.2% Triton
X-100 (Acros Organics) and 5% donkey serum (Sigma) for 1 h. Cells were incu-
bated overnight at 4 °C in blocking buffer (2% donkey serum) containing the
different primary antibodies (Abs). After washing with PBS, cells were incubated
with secondary Abs (Invitrogen) for 1 h at room temperature. Primary Abs and
dilutions are listed in Supplementary Table 3.
Fluorescent and bright ﬁeld micrographs were captured using a Zeiss Axio
Imager M1 microscope (Carl Zeiss) equipped with an AxioCam MRc5 (bright ﬁeld,
Carl Zeiss) or a monochrome AxioCam Mrm camera (ﬂuorescence, Carl Zeiss).
Images were analyzed using ImageJ with Coloc2 plug-in. Pearson’s
correlation coefﬁcients were used for expressing the intensity correlation for
colocalization.
Axonal transport analysis. Motor neurons (day 24, 31, and 38) from patients and
controls were loaded with MitoTracker-Red (50 nM, Invitrogen) or ER Tracker-
Red (1 µM, Invitrogen), washed and left to equilibrate (20 min) in motor neuron
maturation medium, before transferring them to a HEPES buffered salt solution
(pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM glucose, 10
mM HEPES). Measurements were performed on an inverted Zeiss Axiovert 200M
microscope (Carl Zeiss) with a ×40 water immersion lens.
Motor neurons were selected under differential interference optics (DIC) based
on typical morphology consisting of a soma and long-extended neurites. Both
MitoTracker-RED and ER Tracker-Red were excited at 580 nm, using a TILL Poly
V light source (TILL Photonics) and image sequences were recorded (200 images at
1 Hz) onto a cooled CCD camera (PCO Sensicam-QE) using TillVisION (TILL
Photonics) software. A heated gravity-fed perfusion system was used to keep cells
at 36± 0.5 °C during the recordings.
All image analysis was performed in Igor Pro (Wavemetrics) using custom-
written routines based on a previously described analysis algorithm54. In brief,
kymographs or spatio-temporal maps were constructed for each of the neuronal
processes. In these maps, stationary mitochondria appear as vertical lines and
moving mitochondria generate tilted lines. Proportions of moving and stationary
mitochondria were extracted from the maps by marking and analyzing the
properties of each of the mitochondrial trajectories.
Electron microscopy. MNs were plated on plastic coverslips on the tenth day of
differentiation. On day 38, cells were ﬁxed and processed for embedding and
ultrathin sectioning. Subsequently, the samples were contrasted with uranyl acetate
and lead citrate as described before55. MNs were identiﬁed by their morphology
and were analyzed by using a JEOL JEM1400 transmission electron microscope
(JEOL, Tokyo, Japan). Digital acquisitions were taken by a numeric camera
(Quemesa; Soft Imaging System, Berlin, Germany).
Statistical analysis. A minimum of three independent experiments based on three
different differentiation batches was always performed. Statistical analysis was
performed using Graphpad Prism version 5.0b.
Mann–Whitney test were used as statistical analysis for patch clamp data.
One-way ANOVA was used for the other experiments with post-hoc Tukey’s test
to determine statistical differences between groups.*P< 0.05, **P< 0.01,
***P< 0.001, ****P< 0.0001 were considered signiﬁcant. Data values represent
mean± SEM, unless indicated otherwise.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding authors upon reasonable request.
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